Anavex Life Sciences Corp (NASDAQ:AVXL) Expected to Post Earnings of -$0.17 Per Share
Equities research analysts forecast that Anavex Life Sciences Corp (NASDAQ:AVXL) will post ($0.17) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Anavex Life Sciences’ earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.18). Anavex Life Sciences posted earnings per share of ($0.06) in the same quarter last year, which would suggest a negative year over year growth rate of 183.3%. The company is expected to announce its next quarterly earnings report on Thursday, August 8th.
According to Zacks, analysts expect that Anavex Life Sciences will report full-year earnings of ($0.68) per share for the current year, with EPS estimates ranging from ($0.70) to ($0.65). For the next year, analysts anticipate that the firm will report earnings of ($0.81) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Anavex Life Sciences.
Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01.
Shares of NASDAQ AVXL traded up $0.03 during midday trading on Wednesday, hitting $3.06. The company had a trading volume of 1,049,633 shares, compared to its average volume of 407,270. Anavex Life Sciences has a twelve month low of $1.25 and a twelve month high of $4.09. The firm has a 50-day simple moving average of $3.22. The firm has a market cap of $156.89 million, a price-to-earnings ratio of -7.85 and a beta of 2.38.
A number of large investors have recently bought and sold shares of AVXL. Park West Asset Management LLC increased its holdings in Anavex Life Sciences by 1.6% during the 4th quarter. Park West Asset Management LLC now owns 3,495,615 shares of the biotechnology company’s stock valued at $5,453,000 after acquiring an additional 53,450 shares in the last quarter. Deutsche Bank AG purchased a new position in Anavex Life Sciences during the 4th quarter valued at about $28,000. Tibra Equities Europe Ltd purchased a new stake in shares of Anavex Life Sciences during the first quarter worth about $258,000. Edge Wealth Management LLC grew its holdings in shares of Anavex Life Sciences by 200.0% during the first quarter. Edge Wealth Management LLC now owns 30,000 shares of the biotechnology company’s stock worth $91,000 after buying an additional 20,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Anavex Life Sciences during the first quarter worth about $152,000. Hedge funds and other institutional investors own 14.27% of the company’s stock.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
Featured Article: Do Tariffs Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.